Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Medicina (Kaunas) ; 57(5)2021 Apr 28.
Article in English | MEDLINE | ID: covidwho-1389438

ABSTRACT

Carbapenem-resistant Enterobacteriaceae (CRE) are a serious public health threat. Infections due to these organisms are associated with significant morbidity and mortality. Among them, metallo-ß-lactamases (MBLs)-producing Klebsiella pneumoniae are of global concern today. The ceftazidime/avibactam combination and the ceftazidime/avibactam + aztreonam combination currently represent the most promising antibiotic strategies to stave off these kinds of infections. We describe the case of a patient affected by thrombotic thrombocytopenic purpura (TTP) admitted in our ICU after developing a hospital-acquired SarsCoV2 interstitial pneumonia during his stay in the hematology department. His medical conditions during his ICU stay were further complicated by a K. Pneumoniae NDM sepsis. To our knowledge, the patient had no risk factors for multidrug-resistant bacteria exposure or contamination during his stay in the hematology department. During his stay in the ICU, we treated the sepsis with a combination therapy of ceftazidime/avibactam + aztreonam. The therapy solved his septic state, allowing for a progressive improvement in his general condition. Moreover, we noticed that the negativization of the hemocultures was also associated to a decontamination of his known rectal colonization. The ceftazidime/avibactam + aztreonam treatment could not only be a valid therapeutic option for these kinds of infections, but it could also be considered as a useful tool in selected patients' intestinal decolonizations.


Subject(s)
COVID-19 , Cross Infection , Purpura, Thrombotic Thrombocytopenic , Sepsis , Anti-Bacterial Agents/therapeutic use , Azabicyclo Compounds/therapeutic use , Aztreonam/therapeutic use , Ceftazidime/therapeutic use , Cross Infection/drug therapy , Drug Combinations , Humans , Klebsiella pneumoniae/genetics , Microbial Sensitivity Tests , Purpura, Thrombotic Thrombocytopenic/drug therapy , RNA, Viral , SARS-CoV-2 , Sepsis/drug therapy , beta-Lactamases
SELECTION OF CITATIONS
SEARCH DETAIL